Glioblastoma patients in 2026 can access personalized immunotherapy through specialized cancer centers offering clinical trials that customize vaccines or cell therapies based on individual tumor molecular profiles. Key Takeaways Personalized glioblastoma immunotherapy remains investigational in 2026, accessible through clinical trials involving tumor sequencing and patient-specific vaccine or cell therapy manufacturing Three protocol types dominate the landscape: dendritic c

A criterion-based guide to selecting oncologists for personalized cancer treatment. Compare hospital vs clinic models, evaluate precision oncology capabilities, tumor boards, and pricing transparency.